National Board of Examinations

Overtion Demov Name .	DrNB Clinical Immunology and
Question Paper Name :	Rheumatology Paper1
Subject Name :	DrNB Clinical Immunology and
Subject Name .	Rheumatology Paper1
Creation Date :	2022-12-22 22:33:51
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No
DrNB Clinical Immunology ar	nd Rheumatology Paper1
DrNB Clinical Immunology ar Group Number:	nd Rheumatology Paper1
Group Number :	1
Group Number : Group Id :	1 3271871299
Group Number : Group Id : Group Maximum Duration :	1 3271871299 0
Group Number : Group Id : Group Maximum Duration : Group Minimum Duration :	1 3271871299 0 180
Group Number : Group Id : Group Maximum Duration : Group Minimum Duration : Show Attended Group? :	1 3271871299 0 180 No
Group Number : Group Id : Group Maximum Duration : Group Minimum Duration : Show Attended Group? : Edit Attended Group? :	1 3271871299 0 180 No
Group Number : Group Id : Group Maximum Duration : Group Minimum Duration : Show Attended Group? : Edit Attended Group? : Group Marks :	1 3271871299 0 180 No No
Group Number : Group Id : Group Maximum Duration : Group Minimum Duration : Show Attended Group? : Edit Attended Group? : Group Marks : Is this Group for Examiner? :	1 3271871299 0 180 No No No No

DrNB Clinical Immunology and Rheumatology Paper1

Section Id: 3271871302

Section Number:

Section type: Offline

Mandatory or Optional: Mandatory

Number of Questions to be attempted: 10

Section Marks: 100

Enable Mark as Answered Mark for Review and

Clear Response:

Yes

Maximum Instruction Time: 0

Sub-Section Number: 1

Sub-Section Id: 3271871306

Question Shuffling Allowed: No

Is Section Default?: null

Question Number: 1 Question Id: 32718712042 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

- 1. a) Write mechanism of action of hydroxychloroquine (HCQ) with appropriate diagram. [5]
- b) Write utility of therapeutic drug monitoring of HCQ. [3]
- c) Enlist the factors associated with HCQ induced ophthalmic toxicity. [2]

Question Number: 2 Question Id: 32718712043 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Describe newer antibodies in systemic sclerosis. [5]

b) How do scleroderma antibodies guide therapeutic decisions and management? [5]

Question Number: 3 Question Id: 32718712044 Question Type: SUBJECTIVE Consider As

Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Elaborate on type 1 interferon signalling pathway in rheumatic diseases with the use of

diagram. [7]

b) What is the evidence for importance of this pathway in pathogenesis of systemic sclerosis? [3]

Question Number: 4 Question Id: 32718712045 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time:0

Correct Marks: 10

a) Describe with diagram the structure of synovium. [3]

b) Discuss in detail the types and properties of synovial lining cells. [2+5]

Question Number: 5 Question Id: 32718712046 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Describe with diagram the process of bone remodelling. [6]

b) Discuss in brief the markers of bone turnover. [4]

Question Number: 6 Question Id: 32718712047 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Describe in brief classification of dendritic cells. [3]

b) How does dendritic cell serve as a bridge between innate and adaptive immune system, discuss

with diagram? [4]

c) Briefly discuss dendritic cell vaccines in autoimmune rheumatic diseases. [3]

Question Number: 7 Question Id: 32718712048 Question Type: SUBJECTIVE Consider As

Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Discuss the outcome measures, strengths, and weakness of case control study. [1+2+2]

b) What are methods to minimise weaknesses of a case control study? [3]

c) How is case control study different from a self-controlled study? [2]

Question Number: 8 Question Id: 32718712049 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

A 30-year-old lady presented with pain and swelling of multiple joints. She was tested for anticitrullinated protein antibodies (ACPA):

a) Enlist different ACPA in patients with Rheumatoid arthritis. [3]

b) Discuss clinical relevance of ACPA in Rheumatoid arthritis. [5]

c) What is the utility of ACPA in preclinical Rheumatoid arthritis? [2]

Question Number: 9 Question Id: 32718712050 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Describe T cell receptor with appropriate diagram. [5]

b) Write a brief note on CART cell. [3]

c) List the autoimmune rheumatic diseases with potential use of CART therapy. [2]

Question Number : 10 Question Id : 32718712051 Question Type : SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

- a) Write briefly on mature B cell subsets. [6]
- b) Discuss the role of mature B cell subsets as biomarkers in systemic vasculitis. [4]